Share Name Share Symbol Market Type Share ISIN Share Description
Omega Diagnostics Group Plc LSE:ODX London Ordinary Share GB00B1VCP282 ORD 4P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  2.00 2.13% 96.00 95.00 96.00 103.00 90.50 94.00 6,573,908 16:35:02
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 9.8 1.2 0.8 120.0 172

Omega Diagnostics Group PLC Exercise of Options and Total Voting Rights

14/09/2020 7:00am

UK Regulatory (RNS & others)

Omega Diagnostics (LSE:ODX)
Historical Stock Chart

From Aug 2020 to Oct 2020

Click Here for more Omega Diagnostics Charts.


RNS Number : 8031Y

Omega Diagnostics Group PLC

14 September 2020

14 September 2020


("Omega" or the "Company" or the "Group")

Exercise of Options and Total Voting Rights

Omega Diagnostics (AIM: ODX), the medical diagnostics company focused on CD4, infectious diseases and food intolerance testing, announces that it has allotted 40,000 new ordinary shares of 4 pence each in the capital of the Company ("Ordinary Shares") following the exercise of share options by an employee.

Application will be made to the London Stock Exchange for the 40,000 new Ordinary Shares to be admitted to trading on AIM ("Admission") and it is expected that Admission will become effective and trading will commence at 8.00 a.m. on 18 September 2020.

After Admission, the total number of Ordinary Shares in issue will be 178,493,110 and the total number of voting rights will therefore be 178,493,110. This figure may be used by shareholders as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the share capital of the Company under the FCA's Disclosure and Transparency Rules.

The information contained within this announcement is deemed by the Company to constitute inside information stipulated under the Market Abuse Regulation (EU) No. 596/2014.The below notification is made in accordance with the requirements of the EU Market Abuse Regulation.


 Omega Diagnostics Group PLC                      Tel: 01259 763 030 
 Colin King, Chief Executive       
 Kieron Harbinson, Group Finance Director 
 finnCap Ltd                                      Tel: 020 7220 0500 
 Geoff Nash / Teddy Whiley (Corporate 
 Alice Lane (ECM) 
 Walbrook PR Limited                           Tel: 020 7933 8780 or 
 Paul McManus                                     Mob: 07980 541 893 
 Lianne Cawthorne                                 Mob: 07584 391 303 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact or visit

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.



(END) Dow Jones Newswires

September 14, 2020 02:00 ET (06:00 GMT)

1 Year Omega Diagnostics Chart

1 Year Omega Diagnostics Chart

1 Month Omega Diagnostics Chart

1 Month Omega Diagnostics Chart
ADVFN Advertorial
Your Recent History
Omega Diag..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V:gb D:20201021 02:01:19